Cite
HARVARD Citation
Wollenberg, A. et al. (2020). Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). British journal of dermatology. pp. 1120-1135. [Online].